Metabolic & GLP-1preliminary · human data
GLP-1 dropouts fall overall, rise from side-effects
Pooling randomised trials, people assigned GLP-1 receptor agonists for overweight or obesity had a 37% lower risk of overall nonadherence than controls (RR 0.63), yet were more than twice as likely to stop because of adverse reactions (RR 2.29), mainly gastrointestinal ones.
What it shows: Systematic review and meta-analysis of randomised trials in adults with overweight or obesity searched to October 2024; the number of trials and participants is not reported in the abstract, adherence definitions vary between trials, and trial conditions with regular monitoring tend to flatter persistence compared with real-world use.Review · Obes Rev